Drugs that contain Avatrombopag Maleate

1. List of Doptelet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7638536 AKARX INC 2-Acylaminothiazole derivative or salt thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765764 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jan, 2023

(22 days ago)

US8338429 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jun, 2023

(4 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 21, 2023
Orphan Drug Exclusivity (ODE) Jun 26, 2026
New Indication (I) Jun 26, 2022

NCE-1 date: May, 2022

Market Authorisation Date: 21 May, 2018

Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure; Treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic